Paying users zone. Data is hidden behind .
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. (BMY)
Analysis of Solvency Ratios
Beginner level
Solvency ratios also known as long-term debt ratios measure a company’s ability to meet long-term obligations.
Solvency Ratios (Summary)
Bristol-Myers Squibb Co., solvency ratios
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Debt Ratios | ||||||
Debt to equity | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Debt to capital | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Debt to assets | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Financial leverage | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Coverage Ratios | ||||||
Interest coverage | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Fixed charge coverage | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to equity ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to capital ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Bristol-Myers Squibb Co.’s debt to assets ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s financial leverage ratio increased from 2016 to 2017 but then slightly decreased from 2017 to 2018. |
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co.’s interest coverage ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Bristol-Myers Squibb Co.’s fixed charge coverage ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
Debt to Equity
Bristol-Myers Squibb Co., debt to equity calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Long-term debt, excluding current portion | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total debt | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total Bristol-Myers Squibb Company shareholders’ equity | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Solvency Ratio | ||||||
Debt to equity1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Debt to Equity, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Debt to Equity, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Debt to Equity, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Debt to equity = Total debt ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷
=
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to equity ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Debt to Capital
Bristol-Myers Squibb Co., debt to capital calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Long-term debt, excluding current portion | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total debt | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total Bristol-Myers Squibb Company shareholders’ equity | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total capital | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Solvency Ratio | ||||||
Debt to capital1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Debt to Capital, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Debt to Capital, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Debt to Capital, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷
=
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Bristol-Myers Squibb Co.’s debt to capital ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Debt to Assets
Bristol-Myers Squibb Co., debt to assets calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Long-term debt, excluding current portion | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total debt | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total assets | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Solvency Ratio | ||||||
Debt to assets1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Debt to Assets, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Debt to Assets, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Debt to Assets, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷
=
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Bristol-Myers Squibb Co.’s debt to assets ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Financial Leverage
Bristol-Myers Squibb Co., financial leverage calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Total assets | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total Bristol-Myers Squibb Company shareholders’ equity | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Solvency Ratio | ||||||
Financial leverage1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Financial Leverage, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Financial Leverage, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Financial Leverage, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Financial leverage = Total assets ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= ÷
=
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co.’s financial leverage ratio increased from 2016 to 2017 but then slightly decreased from 2017 to 2018. |
Interest Coverage
Bristol-Myers Squibb Co., interest coverage calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings attributable to BMS | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Add: Net income attributable to noncontrolling interest | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Add: Income tax expense | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Add: Interest expense | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Earnings before interest and tax (EBIT) | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Solvency Ratio | ||||||
Interest coverage1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Interest Coverage, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Interest Coverage, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Interest Coverage, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷
=
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co.’s interest coverage ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Fixed Charge Coverage
Bristol-Myers Squibb Co., fixed charge coverage calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings attributable to BMS | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Add: Net income attributable to noncontrolling interest | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Add: Income tax expense | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Add: Interest expense | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Earnings before interest and tax (EBIT) | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Add: Operating lease expense | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Earnings before fixed charges and tax | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Interest expense | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Operating lease expense | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Fixed charges | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Solvency Ratio | ||||||
Fixed charge coverage1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Fixed Charge Coverage, Competitors2 | ||||||
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Fixed Charge Coverage, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Fixed Charge Coverage, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷
=
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Bristol-Myers Squibb Co.’s fixed charge coverage ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |